National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) sits in the top decile of US sponsors by registered trial count (#253 of 15,742 sponsors by registered trial count).
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): 93 sponsored US clinical trials, 12 recruiting.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) sponsors 93 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 71 completed. 4 of these trials are in Phase 3-4 (later-stage) and 45 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Arthritis, with 4 trials.
Top-decile sponsor footprint
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ranks in the top decile of sponsors by registered trial count (#253 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
71 of 80 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
93 total, page 2 of 2
Muscle Strengthening Device for Knee Osteoarthritis
NCT00007241
Effects of Exercise Poles on Older Adults During Exercise Walking
NCT00037167
Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis Patients
NCT00014794
Humanized LL2IGG to Treat Systemic Lupus Erythematosus
NCT00011908
Registry for African Americans With Early Rheumatoid Arthritis
NCT00074555
Study of Arthritis and Related Conditions
NCT00006333
Scleroderma Registry
NCT00074568
Consortium for the Longitudinal Evaluation of African Americans With Early Rheumatoid Arthritis (The CLEAR Registry)
NCT00815425
Infliximab for the Treatment of Early Rheumatoid Arthritis
NCT00006292
Scalp Psoriasis Treatment With a Fiber Optic Comb
NCT00007293
Etanercept for Wegener's Granulomatosis
NCT00005007
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
NCT00005571
Oral Type I Collagen for Relieving Scleroderma
NCT00005675
Treatment of Psoriasis With Parathyroid Hormone
NCT00007306
High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide
NCT00005778
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
NCT00000433
Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis
NCT00000430
dnaJ Peptide for Relieving Rheumatoid Arthritis
NCT00000435
Genetics of Ankylosing Spondylitis
NCT00081562
BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis
NCT00001789
Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients
NCT00001679
Genetics of Rheumatoid Arthritis
NCT00001678
Osteoporosis Prevention in Preadolescent Girls
NCT00000413
Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy
NCT00001677
The Acquisition of Blood and Skin Samples From Normal Volunteers to Support Research Activities on Dermatologic Diseases
NCT00001505
Cyclophosphamide and Fludarabine to Treat Lupus Nephritis
NCT00001676
Evaluation and Treatment of Patients With Dermatologic Diseases
NCT00001506
Tidal Lavage in Knee Osteoarthritis
NCT00000424
Methimazole to Treat Polymyositis and Dermatomyositis
NCT00001421
A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
NCT00001422
Study of Psoriatic Arthritis
NCT00001420
Juvenile Rheumatoid Arthritis Research Registry
NCT00090571
National Registry for Ichthyosis and Related Disorders
NCT00074685
The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis
NCT00001375
Steroid Hormones, TH1/TH2 Cytokines and Reproductive Status
NCT00001376
Improving Functional Recovery After Hip Fracture
NCT00000436
Genetic and Family Studies of Inherited Muscle Diseases
NCT00001331
Study of Silicone-Associated Connective Tissue Diseases
NCT00001330
Study and Treatment of Inflammatory Muscle Diseases
NCT00001265
Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions
NCT00001291
Isotretinoin in Preventing Skin Cancer
NCT00025012
Impact of Exercise on Older Persons With Osteoarthritis
NCT00000434
Prevention of Steroid-Induced Osteoporosis in Children
NCT00022841
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 27 |
| Phase 3 | 4 |
Therapeutic Areas
What is open in the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) pipeline
12 recruiting of 93 indexed (13% open); 71 completed (76%).
Phase mix: 4 late (III/IV) vs 45 early (I/II) (early-phase heavy).
Top condition: Arthritis (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): open-pipeline peers nationwide
Peers matched on 93 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 93 trials (± recruiting share)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 93 trials · 17% recruiting
- Roxane Laboratories · 93 trials · 0% recruiting
- Colorado State University · 94 trials · 21% recruiting
- Endeavor Health · 94 trials · 20% recruiting
Sponsors near 13% open enrollment (± trial volume)
- McMaster University · 13% recruiting · 31 trials
- Temple University · 13% recruiting · 163 trials
- University of Pittsburgh · 13% recruiting · 1,238 trials
- Intermountain Health Care · 13% recruiting · 85 trials
Related
What to do with this National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) page
93 registered trials is a research-attention snapshot, not an endorsement of National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) or any single study.
- 12 of National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Arthritis is the condition National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Arthritis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) pipeline card: 93 registered trials from official public datasets.Report a data error.